# Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus

> **NCT04046133** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Cardiff University** · enrollment: 52 (actual)

## Conditions studied

- Anal Cancer Stage III A
- Anal Cancer Stage III B

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04046133
- **Lead sponsor:** Cardiff University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-19
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04046133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04046133, "Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04046133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*